Published on : Jan 13, 2016
Albany, New York, January 13, 2016: The global pancreatic cancer therapeutics market is largely fueled by the increase in diabetes, rise in global aging population, and the growing prevalence of obesity. The report, titled “Pancreatic Cancer Therapeutics in Major Developed Markets to 2021 - Strong Late Stage Pipeline Holds Promise for Increasingly Diverse Market Landscape”, states that the global market for pancreatic cancer is anticipated to expand at a 7.60% CAGR during the forecast period, rising from a value of US$1.7 bn in 2014 to US$2.9 bn by 2021.
Pancreatic cancer is predominantly a disease that affects the elderly, with 75.0% of cases diagnosed in people over the age of 75. At present, there are no methods in use for the early detection of pancreatic cancer, making resection the best option for patient survival. There is, as a result, a clear clinical demand for diverse treatment options. Even though late-stage drugs that are currently under development to address this clinical need, the results have been rather limited as far as efficacy is concerned.
For more info, get a PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=499497
The global pancreatic cancer therapeutics market is studied on the basis of phase and geography. By phase, the pipeline drugs are segmented into discovery, preclinical, phase I, phase II, phase III, and pre-registration. By geography, the report studies the global pancreatic cancer therapeutics market, and markets in the US, the UK, Germany, Spain, Canada, France, Italy, and Japan. Some of the key aspects covered in the pancreatic cancer therapeutics market and supported by descriptive tables are symptoms and causes, common mutations in pancreatic cancer, inherited mutation information, survival by stage, key molecular targets in the pipeline, common endpoints in oncology clinical trials, clinical trial failure rate, average duration of clinical trials, and mechanism of action.
In addition to identifying the key factors driving the global pancreatic cancer therapeutics market, the research report highlights the major challenges that pose a threat to its development over the course of the forecast period. The growing prevalence of pancreatic cancer across all target markets, rising disease awareness, high level of unmet need in all treatment segments, improved diagnostics, rise in orphan indication incentives, and increased number of candidates in late-stage drug development are the core forces boosting the market for pancreatic cancer therapeutics. On the down side, high failure rates, typical late stage of diagnosis, high genetic heterogeneity of pancreatic cancer, and restriction of premium pricing owing to availability of generics are the leading factors that are likely to prove detrimental for the growth of the pancreatic cancer therapeutics market.
The research report offers clients a complete understanding of the present commercial and clinical landscape of the pancreatic cancer therapeutics market by taking into consideration disease pathogenesis, diagnosis, prognosis, and treatment options. The pipeline is thoroughly analyzed, presenting a clear visual outline of the results.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org